SciSparc Subsidiary Seeks FDA Orphan Drug Status for Tourette Drug

Regulation
โดย NewMediaWire·US·Read original
Summary · why it matters

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs Inc., is pursuing U.S. Food and Drug Administration Orphan Drug Designation for SCI-110, its drug candidate for treating adults with Tourette Syndrome, and has engaged RK Strategies, a U.S. government and public affairs firm, to support the regulatory pathway. The designation, if granted, could strengthen the product's market profile, as it is reserved for therapies targeting rare diseases affecting fewer than 200,000 people in the United States. SCI-110, a cannabinoid-based candidate combining dronabinol and palmitoylethanolamide, recently advanced into a Phase IIb program at three academic centers, building on Phase IIa results that showed an average tic reduction of 21% as measured by the Yale Global Tic Severity Scale. The engagement with RK Strategies aims to boost visibility among federal stakeholders and reinforce the importance of new treatment options for adult Tourette Syndrome.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Scisparc Ltd
SPRC
▲ PositiveRegulationrelevance

SciSparc's subsidiary is pursuing FDA Orphan Drug Designation for SCI-110 in Tourette Syndrome, a regulatory pathway that could strengthen the product's market profile.

Theme Impact 1

Off-coverage companies 2

NeuroThera Labs Inc.Private▲ Positive
Regulationrelevance

NeuroThera Labs is the subsidiary seeking FDA Orphan Drug Designation for its SCI-110 Tourette candidate and advancing it into Phase IIb.

RK Strategies, Inc.Private± Mixed
relevance

RK Strategies is engaged to support the regulatory pathway and boost federal visibility, but the article gives no substantive impact on the firm itself.

Related news

Axsome Therapeutics Reports New Clinical Data in Depression and Alzheimer's Agitation

Axsome Therapeutics reported new clinical data in major depressive disorder and Alzheimer's disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome's central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms, and management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. The company is advancing multiple late-stage clinical programs, including AXS-05, AXS-12, AXS-14, and several solriamfetol indications, and the fresh congress results give more clinical detail around AXS-05 in depression and Alzheimer's agitation, feeding the thesis that future CNS indications can broaden the revenue mix beyond Auvelity, Sunosi and SYMBRAVO. Axsome, a mid-sized US pharmaceuticals player with a market cap of $11.2b, competes alongside larger CNS-focused drug developers such as Biogen and Eli Lilly and smaller specialists. The same update also stress tests a key risk: management must commercialise several CNS assets at once while running high R&D and SG&A spending, with payer scrutiny and strong rivals in both categories.
AXSM ▲
Biotech & Genomic Medicine
Simply Wall St·6hRead more →
▲2

Novartis Acquires Full Rights to Sironax Brain Delivery Platform

Novartis agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier, expanding its toolkit for research into central nervous system disorders where treatment options remain limited. Novartis is a large pharmaceuticals group with a CHF218.8 billion market cap that researches, develops, manufactures, distributes, markets, and sells medicines globally, so gaining access to differentiated delivery technology directly links into its existing focus on complex neurological treatments. The Sironax platform speaks to the same advanced-therapy thesis that underpins Cosentyx's CHMP progress and remibrutinib's Phase 3 data, as Novartis seeks to own hard-to-reach biology where rivals like Roche and Biogen also compete for neurologists' attention. The flip side is that every new modality adds complexity, and recent trial setbacks such as pelacarsen and del-desiran keep development risk front and center, with analysts flagging that stacking capital-intensive projects on top of share buybacks could stretch the balance sheet of a business already carrying a high level of debt.
NOVN.SW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·7hRead more →
2

AbbVie Unveils New VRAYLAR Real-World and Pediatric Safety Data at Psych Congress 2026

AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.
ABBV ▲
Biotech & Genomic Medicine
Simply Wall St·7hRead more →
© 2026 MarketDXNews